Likewise, a recent study from Rath et al. investigated TCR-engineered T cells in vitro and in vivo strategies to redirect CD4+ T cells against class-I tumor-associated antigens (TAA) epitopes and enhance transgenic CD8+ T cell function [203]. This evidence concerns the gene CD8A and neoplasm.